Daiichi Sankyo Co Liabilities 2024

Daiichi Sankyo Co Aktienanalyse

What does Daiichi Sankyo Co do?

Daiichi Sankyo Co Ltd is a company specialized in the production of medicines. The company was founded in 2005 and was formed from the merger of two Japanese pharmaceutical companies. However, the history of Daiichi Sankyo dates back to 1899 when the Daiichi Group and Sankyo Renkyu merged to form a cooperative. Both companies had been active in the pharmaceutical business since the 1960s and were specialized in the development and production of drugs. Daiichi Sankyo's business model is focused on developing and globally marketing innovative drugs. The company focuses on researching and marketing drugs for the treatment of cancer, cardiovascular diseases, and infectious diseases. Daiichi Sankyo is divided into different divisions. The pharmaceutical division is the company's most important business segment. Here, drugs for various applications are developed and produced, including medications for the therapy of cancer, cardiovascular diseases, and infections. Another division is the medical devices division. Here, medical devices such as catheters and stents for the treatment of cardiovascular diseases, as well as endoscopic devices for the diagnosis and therapy of gastrointestinal diseases, are manufactured. Another important area is the diagnostics division. Here, diagnostic test systems for various applications are developed and manufactured. Some of Daiichi Sankyo's best-known products include the cancer drug Trastuzumab Emtansin and the anticoagulant drug Prasugrel. Daiichi Sankyo is a globally operating company headquartered in Tokyo, Japan. In addition, the company has branches in North, Central, and South America, Europe, Asia, and Oceania. The company places great importance on research and development and participates in numerous collaborations and partnerships with universities and other companies. The goal is to constantly develop new groundbreaking drugs and contribute to the improvement of disease treatment. Overall, Daiichi Sankyo employs approximately 15,000 people worldwide and generates an annual revenue of around 8 billion euros. The company is thus one of the leading companies in the pharmaceutical and medical technology industry and will remain an important player in the global healthcare market in the future. Daiichi Sankyo Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Daiichi Sankyo Co's Liabilities

Daiichi Sankyo Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Daiichi Sankyo Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Daiichi Sankyo Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Daiichi Sankyo Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Daiichi Sankyo Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Daiichi Sankyo Co Stock

What is the level of liabilities of Daiichi Sankyo Co this year?

Daiichi Sankyo Co has a debt balance of 1.06 T JPY this year.

What were the liabilities of Daiichi Sankyo Co compared to the previous year?

The liabilities of Daiichi Sankyo Co have increased by 22.11% increased compared to the previous year.

What are the consequences of high debt for investors of Daiichi Sankyo Co?

High liabilities can pose a risk for investors of Daiichi Sankyo Co, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Daiichi Sankyo Co?

Low liabilities mean that Daiichi Sankyo Co has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Daiichi Sankyo Co affect the company?

An increase in liabilities of Daiichi Sankyo Co can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Daiichi Sankyo Co affect the company?

A decrease in the liabilities of Daiichi Sankyo Co can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Daiichi Sankyo Co?

Some factors that can influence the liabilities of Daiichi Sankyo Co include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Daiichi Sankyo Co so important for investors?

The liabilities of Daiichi Sankyo Co are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Daiichi Sankyo Co take to modify the liabilities?

To change its liabilities, Daiichi Sankyo Co can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Daiichi Sankyo Co pay?

Over the past 12 months, Daiichi Sankyo Co paid a dividend of 35 JPY . This corresponds to a dividend yield of about 0.77 %. For the coming 12 months, Daiichi Sankyo Co is expected to pay a dividend of 35.49 JPY.

What is the dividend yield of Daiichi Sankyo Co?

The current dividend yield of Daiichi Sankyo Co is 0.77 %.

When does Daiichi Sankyo Co pay dividends?

Daiichi Sankyo Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Daiichi Sankyo Co?

Daiichi Sankyo Co paid dividends every year for the past 22 years.

What is the dividend of Daiichi Sankyo Co?

For the upcoming 12 months, dividends amounting to 35.49 JPY are expected. This corresponds to a dividend yield of 0.78 %.

In which sector is Daiichi Sankyo Co located?

Daiichi Sankyo Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Daiichi Sankyo Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Daiichi Sankyo Co from 6/1/2024 amounting to 30 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2024.

When did Daiichi Sankyo Co pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Daiichi Sankyo Co in the year 2023?

In the year 2023, Daiichi Sankyo Co distributed 28.5 JPY as dividends.

In which currency does Daiichi Sankyo Co pay out the dividend?

The dividends of Daiichi Sankyo Co are distributed in JPY.